JP2015514094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514094A5 JP2015514094A5 JP2015503630A JP2015503630A JP2015514094A5 JP 2015514094 A5 JP2015514094 A5 JP 2015514094A5 JP 2015503630 A JP2015503630 A JP 2015503630A JP 2015503630 A JP2015503630 A JP 2015503630A JP 2015514094 A5 JP2015514094 A5 JP 2015514094A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 213
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 63
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 claims description 23
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 23
- 230000002209 hydrophobic effect Effects 0.000 claims description 20
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 13
- 102000045717 human TLR4 Human genes 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 238000013389 whole blood assay Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 39
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617164P | 2012-03-29 | 2012-03-29 | |
| US61/617,164 | 2012-03-29 | ||
| PCT/US2013/034543 WO2013149111A2 (en) | 2012-03-29 | 2013-03-29 | Anti-tlr4 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190726A Division JP2019038816A (ja) | 2012-03-29 | 2018-10-09 | 抗ｔｌｒ４抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514094A JP2015514094A (ja) | 2015-05-18 |
| JP2015514094A5 true JP2015514094A5 (enExample) | 2016-05-19 |
| JP6419064B2 JP6419064B2 (ja) | 2018-11-07 |
Family
ID=48087767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503630A Active JP6419064B2 (ja) | 2012-03-29 | 2013-03-29 | 抗ｔｌｒ４抗体およびその使用 |
| JP2018190726A Pending JP2019038816A (ja) | 2012-03-29 | 2018-10-09 | 抗ｔｌｒ４抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190726A Pending JP2019038816A (ja) | 2012-03-29 | 2018-10-09 | 抗ｔｌｒ４抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9453076B2 (enExample) |
| EP (1) | EP2831117B1 (enExample) |
| JP (2) | JP6419064B2 (enExample) |
| CN (2) | CN107868128A (enExample) |
| AU (1) | AU2013237929B2 (enExample) |
| CA (1) | CA2869048C (enExample) |
| DK (1) | DK2831117T3 (enExample) |
| ES (1) | ES2651692T3 (enExample) |
| HU (1) | HUE037613T2 (enExample) |
| PL (1) | PL2831117T3 (enExample) |
| WO (1) | WO2013149111A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| WO2009101479A2 (en) * | 2007-05-14 | 2009-08-20 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| JP6419064B2 (ja) | 2012-03-29 | 2018-11-07 | ノビミューン エスアー | 抗ｔｌｒ４抗体およびその使用 |
| CA2932787A1 (en) | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
| KR20160125965A (ko) | 2014-02-28 | 2016-11-01 | 아스테라스 세이야쿠 가부시키가이샤 | 신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체 |
| CN104013979B (zh) * | 2014-05-28 | 2016-06-15 | 上海纳米技术及应用国家工程研究中心有限公司 | 肠道靶向造影剂的制备方法 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| CN105949319A (zh) * | 2016-04-27 | 2016-09-21 | 柳州市工人医院 | 作为TLR4信号通路抑制剂用于结肠癌治疗的sTLR4和MD2蛋白复合物 |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| WO2020075171A1 (en) | 2018-10-11 | 2020-04-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Bacteria expressing single chain antibodies against toll-like receptors |
| CA3174429A1 (en) * | 2020-04-20 | 2021-10-28 | Edesa Biotech Research Inc. | Compositions and methods for treatment of acute respiratory distress syndrome |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| JPH07500820A (ja) | 1991-09-05 | 1995-01-26 | ユニバーシティ オブ コネティカット | ポリヌクレオチド又はオリゴヌクレオチドの細胞への標的を定めた送達 |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| ES2382039T3 (es) * | 2003-12-10 | 2012-06-04 | Novimmune Sa | Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos |
| US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| US7674884B2 (en) | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| ES2348792T3 (es) * | 2004-12-10 | 2010-12-14 | Novimmune Sa | TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS. |
| WO2009101479A2 (en) * | 2007-05-14 | 2009-08-20 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
| WO2009138494A2 (en) | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| MX2011004674A (es) * | 2008-11-04 | 2011-05-25 | Idera Pharmaceuticals Inc | Modulacion de la expresion del receptor 4 tipo larga distancia por oligonucleotidos antisentido. |
| CA2806640A1 (en) * | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
| ES2721378T3 (es) * | 2011-01-10 | 2019-07-31 | Novimmune Sa | Anticuerpos anti-TLR4 y métodos de uso de los mismos |
| JP6419064B2 (ja) | 2012-03-29 | 2018-11-07 | ノビミューン エスアー | 抗ｔｌｒ４抗体およびその使用 |
| AU2014338991B2 (en) * | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
| CA2932787A1 (en) * | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
-
2013
- 2013-03-29 JP JP2015503630A patent/JP6419064B2/ja active Active
- 2013-03-29 CN CN201710750112.2A patent/CN107868128A/zh active Pending
- 2013-03-29 WO PCT/US2013/034543 patent/WO2013149111A2/en not_active Ceased
- 2013-03-29 CN CN201380027744.6A patent/CN104540851B/zh active Active
- 2013-03-29 CA CA2869048A patent/CA2869048C/en active Active
- 2013-03-29 DK DK13715871.3T patent/DK2831117T3/en active
- 2013-03-29 HU HUE13715871A patent/HUE037613T2/hu unknown
- 2013-03-29 AU AU2013237929A patent/AU2013237929B2/en active Active
- 2013-03-29 EP EP13715871.3A patent/EP2831117B1/en active Active
- 2013-03-29 ES ES13715871.3T patent/ES2651692T3/es active Active
- 2013-03-29 US US13/853,158 patent/US9453076B2/en active Active
- 2013-03-29 PL PL13715871T patent/PL2831117T3/pl unknown
-
2016
- 2016-09-26 US US15/276,202 patent/US10400044B2/en active Active
-
2018
- 2018-10-09 JP JP2018190726A patent/JP2019038816A/ja active Pending
-
2019
- 2019-07-19 US US16/517,016 patent/US10982004B2/en active Active
-
2021
- 2021-11-15 US US17/526,883 patent/US20220324994A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514094A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2019504032A5 (enExample) | ||
| JP2009518005A5 (enExample) | ||
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2020055849A5 (enExample) | ||
| JP2010180207A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| JP2015504421A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2014526898A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2018521638A5 (enExample) | ||
| FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
| JP2020524661A5 (enExample) | ||
| JP2014512809A5 (enExample) | ||
| RU2016119152A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2013517330A5 (enExample) |